公开(公告)号：US20180296472A1

公开(公告)日：2018-10-18

申请号：US16016335

申请日：2018-06-22

申请人： M et P Pharma AG

发明人： Claudia MATTERN

IPC分类号： A61K9/00 ,  A61K33/00 ,  A61P39/06 ,  A61K47/44 ,  A61K47/26 ,  A61K45/06

摘要： Described herein are methods for reducing the risks of exposure to air pollutants, comprising nasally administering to a subject in need thereof a composition that counteracts the effects of one or more air pollutants, wherein the composition is adapted for nasal administration. In some embodiments the composition comprises an agent that binds to one or more air pollutants, wherein the agent comprises one or both of nonporous silicon dioxide and porous silicon dioxide and/or the composition provides a physical barrier between one or more air pollutants and internal nasal surfaces. Also described are nasal compositions comprising an agent comprising one or both of nonporous silicon dioxide and porous silicon dioxide, a lipophilic or partly lipophilic vehicle, and a surfactant, wherein the composition is adapted for nasal administration. The compositions also may comprise other agents, such as an immunosuppressant. Also described are methods of making and using the compositions.

公开(公告)号：US20200206244A1

公开(公告)日：2020-07-02

申请号：US16815969

申请日：2020-03-11

申请人： M ET P PHARMA AG

发明人： Claudia MATTERN ,  Elisabeth TRAIFFORT ,  Michael SCHUMACHER

IPC分类号： A61K31/568 ,  A61K31/506 ,  A61K31/4436 ,  A61K9/00

摘要： Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.

公开(公告)号：US20210283143A1

公开(公告)日：2021-09-16

申请号：US17157337

申请日：2021-01-25

申请人： M ET P PHARMA AG

发明人： Claudia MATTERN ,  Elisabeth TRAIFFORT ,  Michael SCHUMACHER

IPC分类号： A61K31/568 ,  A61K9/00 ,  A61K31/4436 ,  A61K31/506

摘要： Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.

公开(公告)号：US20180200203A1

公开(公告)日：2018-07-19

申请号：US15716337

申请日：2017-09-26

申请人： M ET P PHARMA AG

发明人： Claudia MATTERN

IPC分类号： A61K31/137 ,  A61K9/16 ,  A61K9/00 ,  A61K9/06 ,  A61K9/127

CPC分类号： A61K31/137 ,  A61K9/0043 ,  A61K9/06 ,  A61K9/127 ,  A61K9/1605

摘要： This invention relates to a galenical gel formulation for nasal administration of neurotransmitters/neuromodulators such as dopamine, serotonin or pregnenolone and progesterone. The special lipophilic or partly lipophilic system of the invention leads to high bioavailability of the active ingredient in plasma and brain caused by sustained serum levels and/or direct or partly direct transport from nose to the brain.